Mirum receives EC approval for LIVMARLI in Alagille syndrome across EU

Mirum Pharmaceuticals, Inc.

European Commission granted marketing authorization for LIVMARLI (maralixibat) oral solution.
Indicated for cholestatic pruritus in Alagille syndrome patients aged 2 months and older.
First and only approved treatment for ALGS in both EU and US; ALGS affects 1 in 30,000 globally.
Approval follows positive CHMP opinion from September 2022.
Authorization covers all 27 EU member states for marketing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.